Elite Pharmaceuticals Targets NASDAQ Listing by 2027 and $27B Anticoagulant Launch in 2028
During the Q2 fiscal 2027 earnings call, Elite Pharmaceuticals (ELTP) outlined a strategic roadmap focused on long-term growth and pipeline expansion. Chairman, CEO, and President Nasrat Hakim highlighted that the company is working toward a NASDAQ listing by March 2027. A major pillar of the company's future valuation rests on its development of an anticoagulant product, which has a targeted launch date in 2028 and represents a potential $27 billion market opportunity. Additionally, management noted that the ADHD product family is currently expanding, strengthening the firm's core business foundation.
Tickers: $ELTP
Topics: earnings call pipeline expansion product development